Get the Stockscreener App
15.12
7.23%
1.02
After Hours:
15.12
Erasca Inc stock is traded at $15.12, with a volume of 4.86M.
It is up +7.23% in the last 24 hours and up +34.52% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$14.10
Open:
$14.31
24h Volume:
4.86M
Relative Volume:
0.94
Market Cap:
$4.68B
Revenue:
-
Net Income/Loss:
$-127.69M
P/E Ratio:
-33.54
EPS:
-0.4508
Net Cash Flow:
$-98.43M
1W Performance:
+12.33%
1M Performance:
+34.52%
6M Performance:
+921.62%
1Y Performance:
+1,045%
1-Day Range:
$14.18
$15.27
1-Week Range:
$12.84
$15.27
52-Week Range:
$1.01
$15.27
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ERAS
Erasca Inc
|
15.12 | 4.37B | 0 | -127.69M | -98.43M | -0.4508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-27-26 | Resumed | Mizuho | Outperform |
| Jan-07-26 | Initiated | Piper Sandler | Overweight |
| Oct-16-25 | Initiated | Stifel | Buy |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-26-25 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | Jefferies | Buy |
| Mar-11-24 | Initiated | CapitalOne | Overweight |
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-11-23 | Initiated | H.C. Wainwright | Buy |
| Mar-30-23 | Initiated | Mizuho | Buy |
| Feb-24-23 | Initiated | Goldman | Buy |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Erasca Inc stock hits 52-week high at $14.63 - Investing.com
Erasca (NASDAQ:ERAS) Hits New 1-Year HighShould You Buy? - MarketBeat
Erasca, Inc. (ERAS): A Bull Case Theory - Yahoo Finance
Erasca Conference: ERAS Teases 2026 Catalysts for Pan-RAS ERAS-0015 and Pan-KRAS ERAS-4001 - Yahoo Finance
ERAS: Lead RAS-targeted therapies show strong early data, with major trial updates expected in 2024 - TradingView
ERAS: Lead RAS-targeted therapies show promising early results, with key clinical updates expected in 2024 - TradingView
Erasca, Inc. (ERAS) Stock Analysis: Unlocking Potential in Precision Oncology with a Robust Pipeline - DirectorsTalk Interviews
Erasca Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Erasca stock hits 52-week high at $13.30 By Investing.com - Investing.com India
Erasca (NASDAQ:ERAS) Hits New 12-Month HighHere's What Happened - MarketBeat
Erasca stock hits 52-week high at $13.30 - Investing.com
Erasca Granted US Patent for Investigational Drug ERAS-4001 to Treat Solid Tumors - marketscreener.com
Erasca Announces Issuance of a U.S. Patent Covering Pan-KRAS Inhibitor ERAS-4001 - Bitget
New Erasca patent protects ERAS-4001 for RAS-driven cancers to 2043 - Stock Titan
Will Erasca Inc. outperform small cap indexes2025 Pullback Review & AI Optimized Trading Strategy Guides - mfd.ru
Setup Watch: How does Erasca Inc perform in inflationary periods2025 Major Catalysts & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Erasca, Inc. (NASDAQ:ERAS) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Erasca, Inc. (ERAS) Stock Analysis: Clinical-Stage Innovations with a $3.92 Billion Market Cap and High Analyst Support - DirectorsTalk Interviews
Erasca (NASDAQ:ERAS) Sets New 12-Month HighShould You Buy? - MarketBeat
Registration Momentum Builds Across the Oncology Pipeline - The Globe and Mail
Erasca Foundation plans sale of 8,333 shares | ERAS SEC FilingForm 144 - Stock Titan
ERAS PE Ratio & Valuation, Is ERAS Overvalued - Intellectia AI
Can Erasca Inc. stock deliver consistent earnings growthJuly 2025 Retail & Free Technical Pattern Based Buy Signals - mfd.ru
Assessing Erasca (ERAS) Valuation After Early Clinical Signals And Strong Share Price Momentum - Sahm
Can Erasca Inc. stock beat market expectations this quarter2025 Volume Leaders & Daily Profit Maximizing Trade Tips - mfd.ru
Trade Report: Will Erasca Inc outperform small cap indexes2025 Top Decliners & Stepwise Swing Trade Plans - baoquankhu1.vn
ERAS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Erasca Touts Early ERAS-0015 Responses, Potency Edge in Guggenheim Fireside Chat - MarketBeat
Erasca stock today: ERAS rises as traders parse Guggenheim biotech talk, eye next data - Bez Kabli
Will Erasca Inc. be affected by tariffsJuly 2025 Volume & Verified Stock Trade Ideas - mfd.ru
Erasca stock reaches 52-week high at 12.48 USD By Investing.com - Investing.com South Africa
Erasca (NASDAQ:ERAS) Trading Up 6.8%Should You Buy? - MarketBeat
Erasca stock reaches 52-week high at 12.48 USD - Investing.com
ERAS: Early clinical data show promising efficacy and safety for next-generation pan-RAS and pan-KRAS inhibitors - TradingView
What analysts say about Erasca Inc. stockInsider Selling & Free Growth Oriented Trading Recommendations - mfd.ru
Will Erasca Inc. stock go up in YEARTrade Risk Report & Proven Capital Preservation Tips - mfd.ru
Erasca Sees Unusually High Options Volume (NASDAQ:ERAS) - MarketBeat
What sentiment indicators say about Erasca Inc. stock2025 Growth vs Value & Weekly Breakout Watchlists - mfd.ru
Stifel reiterates Buy rating on Erasca stock, maintains $10 price target - Investing.com Australia
Erasca (NASDAQ:ERAS) Sets New 1-Year HighStill a Buy? - MarketBeat
Stifel reiterates Buy rating on Erasca stock, maintains $10 price target By Investing.com - Investing.com South Africa
Erasca (ERAS) Hits Fresh High Anew as Firm Gets up to 267% PT Hike - MSN
Erasca (ERAS) Is Up 15.2% After Upsized Offering Extends Cash Runway For RAS/MAPK Pipeline - simplywall.st
Erasca (NASDAQ:ERAS) Trading 6.4% HigherHere's What Happened - MarketBeat
Erasca to Present at Upcoming Conferences in February - The Manila Times
Erasca (ERAS) Price Target Increased by 60.94% to 10.51 - Nasdaq
Erasca (ERAS) Is Up 10.4% After $225M Follow-On Offering And RAS Pipeline UpdatesHas The Bull Case Changed? - Yahoo Finance
Erasca stock hits 52-week high at $10.71 By Investing.com - Investing.com Nigeria
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):